Interpace nabs European patent covering ThyraMir technology; shares ahead 5%

|About: Interpace Diagnostics ... (IDXG)|By:, SA News Editor

The European Patent Office grants a patent to Interpace Diagnostics Group (IDXG +4.9%) covering the use of microRNAs for distinguishing benign from malignant thyroid neoplasms. The patent protects the underlying technology used in its ThyraMIR microRNA Classifier.